UNIPHARMA is the abbreviated name of “Universal Industries Pharmaceuticals Company” located in the industrial area of Al-Obour city near Cairo, Egypt.
UNIPHARMA is an Egyptian joint stock company established under Egyptian investment laws.
Activities of the UNIPHARMA factory are both human and veterinary pharmaceutical applications.
UNIPHARMA may also participate in other similar fields or modify its primary activity according to the framework of investment law and approval of the General Investment Authority.
Contact
Factory
Address: El-Obour City- 1st. industrial area ,Cairo, Egypt Tel.: +(202) 44812353- 44812234-44812236 Fax: +(202) 44812235
Scientific office
Address : 14 Ramo building, Omer Ibn El-Khttab St., Nasr City, Cairo, Egypt
Tel.: +(202) 23054803 – 23054802
Fax: +(202) 23054801
Export office
Address: 7 Ezzat SalamaSt., from Abbas El-Akad St., Nasr City, Cairo, Egypt
Tel.: +(202) 22748492 – 22873976
Fax: +(202) 22748636
Web: unipharma-eg.com
Once a traditional Swiss pharmaceutical wholesaler, Unipharma has undergone a profound transformation into a globally oriented, strategy-driven partner for hospitals, pharmaceutical, and biotechnology companies. Under the leadership of CEO Simone…
Terry Lin, general manager, and Freia Wei, director for international business at UniPharma, on the company’s move from specialty distribution to drug development and diagnostic products. With an upcoming IPO,…
Dr. Mohamed El Ganayni, Managing Director at UniPharma discusses the challenges in standing out among a crowd of Egyptian pharmaceutical manufacturers, elaborates on his ambitions to become a Top 30…
The latest news from Egyptian healthcare and life sciences, including progress towards the launch of a massive new oncology hospital, why local manufacturer EIPICO is expanding into Kazakhstan, increased governmental…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
The memorandum of understanding includes the localization of manufacturing at EVA Pharma’s specialized and internationally accredited facility for the manufacture of immunosuppressants in the 10th of Ramadan City, Egypt, in…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda.…
Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant…
The leading company in the Egyptian pharma market by volume, the Egyptian International Pharmaceutical Industries Company (EIPICO) is now making a region-first move into biologicals and biosimilars manufacturing to power…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years –…
Egypt country managers tend not to stay in their roles for more than a few years, instead moving on to different pastures when new opportunities arise. However, those that do…
See our Cookie Privacy Policy Here
